Senior Growth Manager, Pendulum Therapeutics
Retention
$140-175k
+ Equity
Reinventing personal health naturally through the microbiome
Open for applications
Reinventing personal health naturally through the microbiome
21-100 employees
Open for applications
$140-175k
+ Equity
21-100 employees
Company mission
To bridge nature and medicine.
Jump to section
Company mission
To bridge nature and medicine.
Our take
Pendulum Therapeutics developed its product by analyzing the genetic material of microbes in the human body. Its debut product, Pendulum Glucose Control is a medical probiotic, the first of its type to be clinically proven to be effective at lowering blood sugar spikes in people with type 2 diabetes. Classified as a medical food, it bridges the gap between medication that can cause side effects and generic probiotic products that have no scientific backup with regards to efficacy.
Pendulum Glucose Control has been greatly in demand, and so with a $54M investment, manufacturing has scaled up. Other products from Pendulum include supplements for gut health and metabolism optimization supplements, the latter also becoming a key product from the team.
In 2023, Pendulum increased its already thriving publicity with the appointment of actor Halle Berry as its CCO, hinting at a scaling up of its operations in line with its media visibility. Its 2024 breakthrough product has been its GLP-1 Probiotic drink, a first-of-its-kind drink to control metabolism.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Walking distance to Bart & Muni
- 401k with company matching
- Strong emphasis on work/life balance: we believe it, we encourage it, we live it
- Flexible schedules and unlimited vacation policy
- Collaborative team environment
- Small on-site gym
- Health, dental, vision, and life insurance
- Commuter benefits
- Competitive salary and equity packages
- Cell phone stipend
- Casual culture (66% of founders usually wear hoodies)
Leadership
John Eid
(CSO & Co-Founder)They took a Ph.D. at The University of Illinois before spending 8 years at Pacific Biosciences. They left this Principal Scientist role in September 2013 to co-found Pendulum Therapeutics, serving since as Chief Scientific Officer.
Colleen Cutcliffe
(CEO & Co-Founder)Having studied for a Ph.D. at John Hopkins University, they worked as a Hospital Project Manager for 3 years prior to joining Elan Pharmaceuticals as a Scientist. They spent 4 years at Pacific Biosciences with John before co-founding Pendulum Therapeutics in 2013.